José Ednésio da Cruz Freire, José Edvar Monteiro Júnior, Daniel Pascoalino Pinheiro, Grayce Ellen da Cruz Paiva Lima, Camila Lopes do Amaral, Victor Rezende Veras, Mayara Ponte Madeira, Erika Bastos Lima Freire, Renan Galvão Ozório, Virgínia Oliveira Fernandes, Ana Paula Dias Rangel Montenegro, Raquel Carvalho Montenegro, Jeová Keny Baima Colares, Renan Magalhães Montenegro Júnior
The current outbreak of COVID-19 cases worldwide has been responsible for a significant number of deaths, especially in hospitalized patients suffering from comorbidities, such as obesity, diabetes, hypertension. The disease not only has prompted an interest in the pathophysiology, but also it has propelled a massive race to find new anti-SARS-CoV-2 drugs. In this scenario, known drugs commonly used to treat other diseases have been suggested as alternative or complementary therapeutics. Herein we propose the use of sitagliptin, an inhibitor of dipeptidyl peptidase-4 (DPP4 ) used to treat type-II diabetes, as an agent to block and inhibit the activity of two proteases, 3CLpro and PLpro , related to the processing of SARS-CoV-2 structural proteins...
December 2022: 3 Biotech